CD19 and congenital rubella syndrome: Data with 1st generation CD19-directed CAR T cells exhibiting a very low risk of high-grade CRS and ICANS, but also inferior outcomes when compared to later-generation CAR T cell products, suggest an important role of cellular engineering and relationship between IEC potency and toxicity.